GleamWall
中文EN

FDMT 4D Molecular Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1650648 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY79,952.5%
TTM net income YoY4.2%
TTM EPS YoY28.0%
Revenue 3-yr CAGR63.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-226.0%
Net margin-208.6%
FCF margin—
EBITDA margin-220.9%

Returns

ROE-56.7%
ROA-47.0%
ROIC (approx.)-53.7%
Asset turnover0.23x

Leverage & solvency

Liabilities / assets21.2%
Debt / equity0.06x
Current ratio6.15x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.83x
Accruals ratio-8.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$4.14M$3.78M$3.05M$85.09M$90,000$15,000$14,000$1,000
R&D expense$69.78M$68.28M$64.98M$57.61M$49.44M$47.95M$40.70M$43.09M
SG&A expense$15.59M$12.52M$11.69M$12.77M$11.84M$11.52M$12.94M$13.03M
Operating income-$81.22M-$77.03M-$73.62M$14.71M-$61.19M-$59.46M-$53.62M-$56.12M
Income tax$0$0$0$0$0$0$0$0
Net income-$78.06M-$72.94M-$68.76M$19.40M-$56.88M-$54.66M-$47.97M-$49.67M
EBITDA-$80.02M-$75.72M-$72.35M$15.93M-$59.88M-$58.16M-$52.57M-$55.02M
EPS (basic)-1.08-1.04-1.01—-1.01-0.98-0.86—
EPS (diluted)-1.08-1.04-1.01—-1.01-0.98-0.86—
Weighted avg. shares (diluted)72.25M70.27M68.06M—56.13M55.93M55.74M—
Balance sheet
Cash & equivalents$39.10M$70.37M$72.49M$60.24M$48.55M$77.16M$133.53M$149.34M
Short-term investments$267.88M$290.96M$318.40M$342.41M$256.51M$216.07M$187.91M$275.54M
Current assets$322.29M$382.96M$405.36M$413.13M$312.38M$303.29M$332.57M$434.93M
PP&E, net$11.22M$12.38M$13.59M$14.87M$16.15M$17.50M$18.75M$19.53M
Total assets$428.75M$492.62M$512.90M$566.71M$423.98M$473.64M$515.73M$560.38M
Current liabilities$52.39M$47.67M$43.40M$43.98M$37.11M$34.68M$26.90M$29.15M
Long-term debt$19.68M$19.59M—$0————
Total debt$19.68M$19.59M—$0————
Total liabilities$90.81M$84.96M$61.07M$61.05M$55.00M$52.75M$46.01M$49.78M
Shareholders' equity$337.94M$407.66M$451.84M$505.66M$368.98M$420.89M$469.72M$510.61M
Net debt-$19.43M-$50.78M—-$60.24M————
Shares outstanding56.37M55.21M52.27M57.61M46.77M46.70M46.32M45.79M
Cash flow statement
Operating cash flow-$56.71M-$70.00M-$68.12M$28.55M-$46.50M-$43.38M-$47.76M-$45.86M
Capital expenditure$49,000——-$70,000-$91,000$66,000$631,000$949,000
Free cash flow-$56.76M——$28.62M-$46.41M-$43.44M-$48.39M-$46.81M
Investing cash flow$24.84M$25.54M$68.89M-$128.85M$17.78M-$13.85M$31.95M$7.06M
Financing cash flow$604,000$42.34M$11.48M$111.98M$116,000$862,000$0$601,000
Depreciation & amortization$1.20M$1.30M$1.27M$1.22M$1.30M$1.30M$1.05M$1.10M
Stock-based compensation$8.26M$5.88M$4.45M$5.55M$4.52M$4.96M$6.99M$7.58M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.